GlycoMimetics Inc (GLYC) Expected to Announce Earnings of -$0.30 Per Share
Equities research analysts expect GlycoMimetics Inc (NASDAQ:GLYC) to post earnings per share of ($0.30) for the current quarter, according to Zacks. Zero analysts have made estimates for GlycoMimetics’ earnings, with the lowest EPS estimate coming in at ($0.34) and the highest estimate coming in at ($0.27). GlycoMimetics reported earnings per share of ($0.24) in the same quarter last year, which indicates a negative year over year growth rate of 25%. The company is expected to issue its next quarterly earnings results on Wednesday, November 14th.
On average, analysts expect that GlycoMimetics will report full year earnings of ($1.24) per share for the current fiscal year, with EPS estimates ranging from ($1.33) to ($1.13). For the next financial year, analysts anticipate that the business will report earnings of ($1.14) per share, with EPS estimates ranging from ($1.85) to ($0.09). Zacks’ EPS averages are an average based on a survey of research analysts that cover GlycoMimetics.
GlycoMimetics (NASDAQ:GLYC) last released its quarterly earnings results on Friday, August 10th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.08.
In other news, SVP John L. Magnani sold 14,200 shares of the company’s stock in a transaction dated Tuesday, October 16th. The stock was sold at an average price of $14.01, for a total value of $198,942.00. Following the transaction, the senior vice president now owns 86,593 shares in the company, valued at approximately $1,213,167.93. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP John L. Magnani sold 25,000 shares of the company’s stock in a transaction dated Thursday, October 18th. The shares were sold at an average price of $14.01, for a total value of $350,250.00. Following the completion of the transaction, the senior vice president now owns 86,593 shares in the company, valued at approximately $1,213,167.93. The disclosure for this sale can be found here. 26.10% of the stock is owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in the business. Alps Advisors Inc. increased its stake in GlycoMimetics by 23.6% in the 3rd quarter. Alps Advisors Inc. now owns 76,195 shares of the biotechnology company’s stock valued at $1,097,000 after buying an additional 14,536 shares during the period. Northern Trust Corp increased its stake in GlycoMimetics by 392.4% in the 2nd quarter. Northern Trust Corp now owns 416,092 shares of the biotechnology company’s stock valued at $6,712,000 after buying an additional 331,581 shares during the period. Bank of New York Mellon Corp increased its stake in GlycoMimetics by 305.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 138,378 shares of the biotechnology company’s stock valued at $2,232,000 after buying an additional 104,248 shares during the period. MetLife Investment Advisors LLC acquired a new position in shares of GlycoMimetics in the second quarter worth $268,000. Finally, Metropolitan Life Insurance Co. NY acquired a new position in shares of GlycoMimetics in the second quarter worth $189,000.
Shares of GLYC stock traded up $0.50 during trading hours on Thursday, reaching $11.93. 375,129 shares of the stock traded hands, compared to its average volume of 558,268. GlycoMimetics has a 1-year low of $10.41 and a 1-year high of $26.05. The firm has a market capitalization of $573.95 million, a P/E ratio of -10.56 and a beta of 3.23.
GlycoMimetics, Inc, a clinical stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. Its advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and has evaluated in a Phase 3 clinical trial, conducted by its strategic collaboration with Pfizer Inc The company's drug candidate, GMI-1271, an E-selectin antagonist, is evaluated in a Phase 1/2 clinical trial as a potential treatment for acute myeloid leukemia and is in a Phase 1 clinical trial for the treatment of multiple myeloma.
Featured Story: Insider Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.